DEF14A

Company

MiNK Therapeutics, Inc.

Filed

December 20, 2024

Period of Report

January 17, 2025

Accession Number

0001140361-24-050096

A DEF 14A is a proxy statement sent to shareholders before an annual meeting. It covers executive compensation, board elections, and shareholder votes. Learn more about DEF 14A filings →